Explore how genomics, comorbidities, and patient goals steer frontline CLL therapy, from fixed-duration venetoclax regimens to continuous BTK inhibitors.
Talha Munir, MBChB, PhD
Advertisement
Articles by Talha Munir, MBChB, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Phase 3 TRIDENT Trial Misses Survival End Point in Glioblastoma
2
Deep Responses Support Push for CAR T-Cell Therapy in AL Amyloidosis
3
FDA Clears Pen Device for Interferon Therapy in Polycythemia Vera
4
FDA Approves Generic Enzalutamide Tablets, Including Higher-Strength Options
5